A Prospective Observational Study of Adult Patients Receiving DUPIXENT for Atopic Dermatitis
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms PROSE
- Sponsors Regeneron Pharmaceuticals
- 03 Dec 2019 Planned End Date changed from 2 Dec 2023 to 31 Dec 2025.
- 03 Dec 2019 Planned primary completion date changed from 2 Dec 2023 to 31 Dec 2025.
- 07 May 2018 Status changed from not yet recruiting to recruiting.